Abstract

Evidence-Based Beyond-Use Dates for Pentravan® Compounded Formulations in Hormone Therapy and Pain Management

Author(s): Polonini Hudson, Kegele Carolina Schettino, Marianni Bruna

Issue: Nov/Dec 2025 - Volume 29, Number 6

Page(s): 505-519

Download in electronic PDF format for $75
  • Evidence-Based Beyond-Use Dates for Pentravan® Compounded Formulations in Hormone Therapy and Pain Management Page 1
  • Evidence-Based Beyond-Use Dates for Pentravan® Compounded Formulations in Hormone Therapy and Pain Management Page 2
  • Evidence-Based Beyond-Use Dates for Pentravan® Compounded Formulations in Hormone Therapy and Pain Management Page 3
  • Evidence-Based Beyond-Use Dates for Pentravan® Compounded Formulations in Hormone Therapy and Pain Management Page 4
  • Evidence-Based Beyond-Use Dates for Pentravan® Compounded Formulations in Hormone Therapy and Pain Management Page 5
  • Evidence-Based Beyond-Use Dates for Pentravan® Compounded Formulations in Hormone Therapy and Pain Management Page 6
  • Evidence-Based Beyond-Use Dates for Pentravan® Compounded Formulations in Hormone Therapy and Pain Management Page 7
  • Evidence-Based Beyond-Use Dates for Pentravan® Compounded Formulations in Hormone Therapy and Pain Management Page 8
  • Evidence-Based Beyond-Use Dates for Pentravan® Compounded Formulations in Hormone Therapy and Pain Management Page 9
  • Evidence-Based Beyond-Use Dates for Pentravan® Compounded Formulations in Hormone Therapy and Pain Management Page 10
  • Evidence-Based Beyond-Use Dates for Pentravan® Compounded Formulations in Hormone Therapy and Pain Management Page 11
  • Evidence-Based Beyond-Use Dates for Pentravan® Compounded Formulations in Hormone Therapy and Pain Management Page 12
  • Evidence-Based Beyond-Use Dates for Pentravan® Compounded Formulations in Hormone Therapy and Pain Management Page 13
  • Evidence-Based Beyond-Use Dates for Pentravan® Compounded Formulations in Hormone Therapy and Pain Management Page 14
  • Evidence-Based Beyond-Use Dates for Pentravan® Compounded Formulations in Hormone Therapy and Pain Management Page 15

Abstract

This bracketed study evaluated the physicochemical stability and microbiological safety of 12 compounded transdermal formulations containing clonazepam (1.0 and 50.0 mg/mL), diclofenac sodium (10.0 and 100.0 mg/mL), estriol (0.1 and 20.0 mg/mL), lidocaine (5.0 and 100.0 mg/mL), melatonin (0.5 and 50.0 mg/mL), and testosterone (5.0 and 100.0 mg/mL) in Pentravan®. Formulations were stored at room temperature for up to 180 days and analyzed at predefined intervals for active pharmaceutical ingredient (API) content, pH, visual characteristics, and antimicrobial effectiveness testing (AET). Most formulations maintained API content within the acceptable range of 90–110% throughout the study, with pH values demonstrating negligible fluctuations. Physical characteristics remained stable over time, with the exception of the diclofenac sodium 100.0 mg/mL formulation, which exhibited phase separation after 30 days. Antimicrobial effectiveness testing confirmed sufficient preservative efficacy for all formulations against Staphylococcus aureus, Escherichia coli, Pseudomonas aeruginosa, Candida albicans, and Aspergillus brasiliensis. The following beyond-use dates (BUDs) were established based on chemical and microbiological stability: 180 days for most APIs; 120 days for lidocaine (5.0 and 100.0 mg/mL); and 60 days for melatonin (0.5 mg/mL). These results reinforce the reliability of Pentravan® as a transdermal vehicle, demonstrating its ability to support stable and microbiologically safe formulations across a wide range of active compounds.

Related Keywords

Related Categories

Printer-Friendly Version

Related Articles from IJPC

Issue/Page
View/Buy
Title/Author
(Click for Abstract / Details / Purchase)
Nov/Dec 2025
Pg. 505-519
May/Jun 2004
Pg. 181-185
Nov/Dec 2025
Pg. 495-504
Mar/Apr 2025
Pg. 163-175
Jan/Feb 2021
Pg. 73-81
Jul/Aug 2004
Pg. 269-274
Jul/Aug 2004
Pg. 320
Author(s): Ashworth Lisa D
Nov/Dec 2014
Pg. 456-460
Jul/Aug 2014
Pg. 278-286
Mar/Apr 2024
Pg. 100-109
Jan/Feb 2014
Pg. 6-12
Jul/Aug 2015
Pg. 295-300
Nov/Dec 2017
Pg. 454-461
Jan/Feb 2001
Pg. 52-54
Author(s): Ford Gina, Garcia Lea
Mar/Apr 2024
Pg. 111-116
Nov/Dec 2018
Pg. 512-515
Nov/Dec 2000
Pg. 414-420
Author(s): Drisko Jeanne A
Jul/Aug 2018
Pg. 303-312
Author(s): Martin Matt
Nov/Dec 2012
Pg. 471-474
Author(s): Osteen Richard
Mar/Apr 2026
Pg. 158-173